Compare Ascendis Pharma A/S (ASND) vs Cloudflare Inc (NET) Price & Performance

Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.

The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.

Cloudflare (NET) trades at $268.40, down 2.61% over 24 hours but remains near recent highs. The stock shows strong technical momentum with bullish moving averages and recent analyst upgrades. Fundamentally, revenue grew to $2.17 billion in 2025, though net income remains negative at -$102 million. Recent news highlights Cloudflare's strategic pivot toward AI infrastructure, including a research pilot with OpenAI announced July 8, 2026.

Outlook remains optimistic due to AI-driven growth potential and consistent earnings beats, but high valuation multiples (P/S 40.36) and negative profitability pose risks. Analyst consensus is strongly bullish with a $250.33 price target, though competition and execution challenges could pressure shareholder returns.